Top China Biopharma Stocks to Watch, According to Bernstein

Bernstein has pinpointed several China-based biopharmaceutical firms that stand to gain from advancing drug development techniques, with a particular emphasis on integrated platforms and services that facilitate AI-driven research and development processes. The brokerage's evaluation underscores quantifiable research and development output, a robust pipeline of programs, and the capacity to merge computational instruments with experimental verification and manufacturing expansion.

1. WuXi AppTec (2359.HK) — Rated as an Outperform, WuXi AppTec aligns with Bernstein's service-provider hypothesis. The company assists in AI-driven drug discovery by offering experimental tools like its OTS compound library. Moreover, expanding collaborations with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) are gaining significance for wet-lab validation, developmental stages, and manufacturing procedures.

2. Innovent Biologics (1801.HK) — According to Bernstein's pipeline assessment, Innovent Biologics has 13 active projects. The broker highlights integrated biopharmaceutical entities capable of integrating AI with datasets covering preclinical, clinical, and commercial phases, rather than focusing solely on AI model creation.

3. Hengrui Medicine (600276.SS) — The brokerage includes Hengrui Medicine in its list of preferred integrated biopharma corporations. Hengrui Medicine currently leads among the companies examined with 74 active programs as of Sept. 28. Bernstein suggests that integrated pharmaceutical manufacturers should be evaluated based on measurable R&D productivity, pipeline refreshment, and clinical execution, not just AI announcements.

4. Hansoh Pharma (3692.HK) — Among established Chinese biopharmaceutical firms, Hansoh Pharma has a considerable number of active programs, with 25 active pipeline programs identified in the latest Bernstein analysis. The bank believes integrated companies possessing proprietary data and end-to-end drug-development capabilities will benefit from AI adoption.